Testing

Autoimmune neurological disorders can often be treated, sometimes with full restoration of function. However, because the symptoms mimic other conditions, autoimmune neurological disorders are frequently misdiagnosed, resulting in an irreversible loss of function.

By Barbara J. Toman • February 11, 2019

numares and Mayo Clinic Laboratories have announced a collaboration to develop clinical diagnostic tests that will measure clusters of risk factors as opposed to individual biomarkers. The unique testing will use nuclear magnetic resonance technology, focusing on cardiovascular disease, kidney disease and liver cancer—among a few other specific diseases.

By Gina Chiri-Osmond • February 5, 2019

In close collaboration with our logistics providers, we have determined that clients can now safely send all specimens to Rochester now that temperatures have moderated. Thank you for your patience and understanding.

By Andy Tofilon • January 30, 2019

A movement disorder might be caused by the body’s immune system, which is meant to fight infections, suddenly attacking the brain. Fortunately, an “autoimmune movement disorder” can often be treated—once its cause is discovered.

By Chris Bahnsen • January 17, 2019

In December 2018, Mayo Clinic Laboratories announced four new tests along with numerous reference value changes, obsolete tests, and algorithm changes. New Tests New tests[...]

By Emily Linginfelter • January 10, 2019

In November 2018, Mayo Clinic Laboratories announced five new tests along with numerous reference value changes, obsolete tests, and algorithm changes.

By Emily Linginfelter • December 13, 2018

In October 2018, Mayo Medical Laboratories announced one new test along with numerous reference value changes, obsolete tests, and algorithm changes.

By Alyssa Frank • November 13, 2018

Necrotizing autoimmune myopathy (NAM) is a serious but rare muscle disease strongly associated with autoantibodies to either the protein signal recognition particle (SRP) or the enzyme 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR). NAM typically manifests with subacute proximal limb muscle weakness and persistently elevated serum creatine kinase (CK) concentrations, but slower onsets can occur and complicate diagnosis.

By Alyssa Frank • October 25, 2018

Chromium and cobalt blood tests are used to monitor exposure to these elements. Both of these elements are naturally occurring and widely distributed in the environment. Previously, serum samples were collected and used to monitor patients with metal-on-metal implants, but serum can easily be contaminated during the harvesting and separation of the serum from the cellular blood components causing incorrect results. By using the new EDTA anticoagulated whole-blood test, which is collected in a trace element tube instead of using serum, the risk of contamination is significantly reduced.

By Alyssa Frank • October 19, 2018

In September 2018, Mayo Medical Laboratories announced two new tests along with numerous reference value changes, obsolete tests, and algorithm changes.

By Alyssa Frank • October 11, 2018

In August 2018, Mayo Medical Laboratories announced one new test along with numerous reference value changes, obsolete tests, and algorithm changes.

By Alyssa Frank • September 20, 2018

Many patients may have flare-ups of their disease, or they may stop responding to treatment. In these situations, the clinician may choose to increase the dose administered or recommend more frequent injections. One cause of decreased response to treatment is the appearance of anti-drug antibodies or “immunogenicity.”

By Mayo Clinic Laboratories • September 7, 2018

Genetic testing is like security-camera video footage of a break-in, providing essential clues to identify a culprit. In certain cancers, the "culprit" might be a rearrangement in a person's DNA, which genomic testing can capture. Mayo Clinic has developed a novel group of clinical tests that zoom in on a person's genome to characterize chromosomal rearrangements.

By Barbara J. Toman • August 20, 2018